Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.58 |
| ▸ | GSK3A | P49840 | 4/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 2/20 | 0.55 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PDE5A | O76074 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785576 | 0.82 | GSK3A (0.64) | GSK3BGSK3AAURKASRCEIF2AK2 | |
| SCHEMBL786402 | 0.81 | GSK3B (0.65) | GSK3BGSK3AAURKASRCEIF2AK2 | |
| SCHEMBL786419 | 0.81 | ABCG2 (0.58) | GSK3BGSK3AAURKASRCEIF2AK2 | |
| SCHEMBL786318 | 0.79 | GSK3B (0.62) | GSK3BGSK3AAURKASRCEIF2AK2 | |
| SCHEMBL786449 | 0.79 | GSK3B (0.60) | GSK3BGSK3AAURKASRCEIF2AK2 | |
| SCHEMBL786163 | 0.79 | GSK3A (0.56) | GSK3BGSK3AAURKASRCEIF2AK2 | |
| SCHEMBL801970 | 0.78 | GSK3B (0.58) | GSK3BGSK3AAURKASRCEIF2AK2 | |
| SCHEMBL786315 | 0.78 | GSK3B (0.62) | GSK3BGSK3AAURKASRCEIF2AK2 | |
| SCHEMBL786252 | 0.78 | GSK3A (0.58) | GSK3BGSK3AAURKASRCEIF2AK2 | |
| SCHEMBL720075 | 0.77 | GSK3B (0.57) | GSK3BGSK3AAURKASRCEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-7951820-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-07 | — | — | US | disclosed |
| US-7691853-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-06 | — | — | US | disclosed |
| US-7473691-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, CDK3, GSK3A | GSK3B 1/4885GSK3A 3/4885AURKA 7/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | GSK3B 1/4885GSK3A 2/4885AURKA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.